Kleanthis Xanthopoulos, Shoreline Biosciences CEO

Off Ed­i­tas’ shelves, iNK cell ther­a­pies float to Shore­line

Ed­i­tas Med­i­cine is of­fload­ing its iNK cell fran­chise and li­cens­ing out some gene edit­ing tech to a pri­vate biotech that counts BeiGene and Gilead’s Kite as friends.

Shore­line Bio­sciences is buy­ing ED­IT-202 and an­oth­er undis­closed iNK pro­gram as part of the deal. MiNK Ther­a­peu­tics had al­so been vy­ing for the pre­clin­i­cal sol­id tu­mor cell ther­a­py, End­points News re­port­ed last fall.

The San Diego biotech al­so ob­tains cer­tain man­u­fac­tur­ing tech, an ex­clu­sive li­cense to Ed­i­tas’ so-called SLEEK gene edit­ing knock-in tech and a non-ex­clu­sive li­cense to the Boston-area biotech’s en­gi­neered As­Cas12a en­zyme.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.